SciELO - Scientific Electronic Library Online

 
vol.15 issue2Brown tumors mimetizing bone metastasic disease as an initial presentation of a parathyroid carcinoma: About a case author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Venezolana de Endocrinología y Metabolismo

Print version ISSN 1690-3110

Abstract

PONTE-N, Carlos I et al. Atherogenic dislipidemia in Latin America: prevalence, causes and treatment. Rev. Venez. Endocrinol. Metab. [online]. 2017, vol.15, n.2, pp.106-129. ISSN 1690-3110.

In the current clinical guidelines, atherogenic dyslipidemia (AD) is a poorly recognized entity. Due to the frequent lipid alterations associated with AD in Latin America (LA), we organized a group of experts named Latin American Academy for the study of Lipids (ALALIP), to generate a document for analyzing its prevalence and to offer practical recommendations. Using the Delphi methodology, we conducted a comprehensive literature review, with emphasis on those publications with implications for LA. Subsequently we developed key questions to be discussed. In LA there is no a global study on risk factors that represent the entire population. The systematic analysis of national health surveys and regional cohort studies showed a consistent high prevalence of the lipid abnormalities that define AD. Low high density lipoprotein cholesterol (HDL-C) ranges from 34.1% to 53.3% and elevated triglycerides (TG) from 25.5% to 31.2%, more prevalent in men. There are multiple causes: high consumption of foods with a high caloric density, cholesterol and trans fats, sedentary lifestyle and epigenetic changes. AD must be well treated with therapeutic changes in lifestyle with increased in physical activities, regular exercise and a diet with a low proportion of carbohydrates y rich in poliunsatured fatty acid, such as omega-3 fatty acid as primary intervention. If needed, this strategie must be supplemented with pharmacological therapies such as monotherapy with statins or a combination of fibrates plus omega-3.fatty acid. Lipid abnormalities that define AD have a high prevalence in LA; the interaction between non-healthy lifestyle, inheritance and epigenetic changes, possibly are its cause. AD is an important cause of cardiovascular residual risk (CVRR), that must be diagnosed and treated. It is important and neccesary to design a global study of risk factors in LA to know the true prevalence of AD.

Keywords : Atherogenic dyslipidemia; triglycerides; triglycerides-rich lipoproteins; Latin America; cardiovascular risk factor; statins; fibrates; omega-3 fatty acid.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )